selleck chemicals llc ALTESS (the Alfuzosin Long-Term Efficacy and Safety Study)36 enrolled more than 1500 men at risk for progression to be randomized to alfuzosin, 10 mg daily, versus placebo. Symptom

score and flow rate improvements in the alfuzosin arms were significantly superior to placebo and maintained for 2 years. Tamsulosin was tested in the CombAT (Combination Therapy with Avodart and Tamsulosin) study,37 in which more than 4500 men at risk for progression were randomized to tamsulosin versus dutasteride versus combination for 4 years. The adjusted mean change in IPSS from baseline to year 4 was −6.3 points for combination therapy versus −3.8 points Inhibitors,research,lifescience,medical (P < .001) for tamsulosin and −5.3

Inhibitors,research,lifescience,medical points (P < .001) for dutasteride. At month 48, the adjusted mean increase in Qmax from baseline was 2.4 mL/s for combination therapy versus 0.7 mL/s (P < .001) for tamsulosin and 2.0 mL/s (P < .05) for dutasteride. Lastly, the MTOPS (Medical Therapy of Prostatic Symptoms) study38,39 enrolled more than 3000 patients randomized to placebo versus doxazosin versus finasteride versus combination therapy in a progression prevention study over 5 years. The 4-year mean reduction in symptom score was 4.9 in the placebo group, 6.6 in the doxazosin group, 5.6 in the finasteride Inhibitors,research,lifescience,medical group, and 7.4 in the combination therapy group. The mean improvement in flow rate was 4.0 mL/s in the doxazosin group, 3.2 mL/s in the finasteride group, and 5.1 mL/s in the combination therapy group. Acute Urinary Retention and Trial Without Catheter Several randomized trials have studied whether the Inhibitors,research,lifescience,medical administration of α-blockers at the time of an acute urinary retention (AUR) event would be beneficial and improve the outcome of a trial

without catheter (TWOC). Two studies performed randomizing patients in AUR to placebo versus alfuzosin suggest that the success rates Inhibitors,research,lifescience,medical may be improved from 47.9% to 61.9% and from 29% to 55%, respectively.40,41 Similar success was found by others using tamsulosin with an improvement from 26% to 48% of successful voiding.42 A Cochran meta-analysis concluded that “the limited available evidence suggests that alpha-blockers increase success rates of TWOC.”43 It may be assumed Tolmetin that this represents a class effect and applies to all α-blockers. Prevention of Progression of LUTS/BPH Three controlled studies focused on the prevention of certain elements of progression of LUTS and clinical BPH using medical therapy, which are the 2-year ALTESS study (placebo vs alfuzosin),36 the 4-year CombAT study (tamsulosin vs dutasteride vs combination),37 and the 5–5.5 year MTOPS study (placebo vs doxazosin vs finasteride vs combination).